We are live on ! Find out more
IMDX

Insight Molecular Diagnostics
IMDX

Fund managers haven’t disclosed any holdings of IMDX yet.

IMDX Hedge Fund Activity: Q1 2026 in Review

41 of the 8,130 institutional investors tracked by Wall St. Rank reported a position in Insight Molecular Diagnostics (IMDX) for Q1 2026, worth a combined $62.1M — down 50% from $125M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new IMDX positions and 7 closed out — a net gain of 10 holders — while 11 added to existing stakes and 6 trimmed.

The largest buyer was Alyeska Investment Group, opening a new position worth an estimated $4.88M. The largest seller was Jane Street, exiting entirely with an estimated $319K sold.

  • 41 institutional investors held Insight Molecular Diagnostics (IMDX) as of Q1 2026, up from 35 in Q4 2025.
  • Funds reported $62.1M of Insight Molecular Diagnostics stock for Q1 2026, down 50% quarter-over-quarter.
  • 17 funds opened new Insight Molecular Diagnostics positions in Q1 2026 and 7 closed out, a net change of +10 holders.
  • The largest Insight Molecular Diagnostics buyer in Q1 2026 was Alyeska Investment Group, an estimated $4.88M added.
  • The largest Insight Molecular Diagnostics seller in Q1 2026 was Jane Street, an estimated $319K sold.

Based on aggregated 13F filings for Q1 2026.